Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 69Letrozole 62Cyclophosphamide 61Paclitaxel 60pertuzumab 52Specimen Handling 52Docetaxel 50abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 33Blood Specimen Collection 33Tamoxifen 32sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × flt3 ligand protein × Breast × Clear all
NCT05029999 2025-08-13

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

University of Texas Southwestern Medical Center

Phase 1 Recruiting
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡